SRPT

NASDAQ · Biotechnology

Sarepta Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$21.49

+0.61 (+2.92%)

As of May 9, 1:30 AM ET ·

SRPT News1 articles

Arrowhead Sees Volatility After S&P MidCap 400 Inclusion, Goldman Eyes 2026 Pipeline

Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.